his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Employment of the Triple Helix concept for development of regenerative medicine applications based on human pluripotent stem cells
University of Skövde, School of Bioscience. University of Skövde, The Systems Biology Research Centre. Cellectis AB, Göteborg, Sweden. (Bioinformatics)
Cellectis AB, Göteborg, Sweden / NovaHep AB, Göteborg, Sweden.
2014 (English)In: Clinical and translational medicine, ISSN 2001-1326, Vol. 3, 1-7 p., 9Article in journal (Refereed) Published
Abstract [en]

Using human pluripotent stem cells as a source to generate differentiated progenies for regenerative medicine applications has attracted substantial interest during recent years. Having the capability to produce large quantities of human cells that can replace damaged tissue due to disease or injury opens novel avenues for relieving symptoms and also potentially offers cures for many severe human diseases. Although tremendous advancements have been made, there is still much research and development left before human pluripotent stem cell derived products can be made available for cell therapy applications. In order to speed up the development processes, we argue strongly in favor of cross-disciplinary collaborative efforts which have many advantages, especially in a relatively new field such as regenerative medicine based on human pluripotent stem cells. In this review, we aim to illustrate how some of the hurdles for bringing human pluripotent stem cell derivatives from bench-to-bed can be effectively addressed through the establishment of collaborative programs involving academic institutions, biotech industries, and pharmaceutical companies. By taking advantage of the strengths from each organization, innovation and productivity can be maximized from a resource perspective and thus, the chances of successfully bringing novel regenerative medicine treatment options to patients increase.

Place, publisher, year, edition, pages
Springer, 2014. Vol. 3, 1-7 p., 9
Keyword [en]
Human pluripotent stem cells, Clinical applications, Regenerative medicine
National Category
Medical and Health Sciences Cell Biology
Identifiers
URN: urn:nbn:se:his:diva-12035DOI: 10.1186/2001-1326-3-9PubMedID: 24872863OAI: oai:DiVA.org:his-12035DiVA: diva2:911907
Funder
Knowledge Foundation
Available from: 2016-03-14 Created: 2016-03-14 Last updated: 2016-03-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sartipy, Peter
By organisation
School of BioscienceThe Systems Biology Research Centre
Medical and Health SciencesCell Biology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 489 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf